Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 20, 2019 - Issue 1
Submit an article Journal homepage
724
Views
3
CrossRef citations to date
0
Altmetric
Articles

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

Bruce RashbaumCapital Medical Associates, Washington, DC, USA; Correspondence[email protected]
View further author information
,
Christoph D. SpinnerUniversity Hospital Klinikum rechts der Isar, Technische Universität München, Munich, Germany; ORCID Iconhttp://orcid.org/0000-0002-3875-5367View further author information
ORCID Icon,
Cheryl McDonaldTarrant County Infectious Disease Associates, Fort Worth, TX, USA; View further author information
,
Cristina MussiniUniversity of Modena and Reggio Emilia, Modena, Italy; View further author information
,
John JezorwskiJanssen Research & Development, LLC, Pennington, NJ, USA; View further author information
,
Donghan LuoJanssen Research & Development, LLC, Titusville, NJ, USA; View further author information
,
Erika Van LanduytJanssen Research & Development, Beerse, Belgium; View further author information
,
Kimberley BrownJanssen Research & Development, LLC, Titusville, NJ, USA; View further author information
&
Eric Y. WongJanssen Scientific Affairs, LLC, Titusville, NJ, USAORCID Iconhttps://orcid.org/0000-0001-7958-2928View further author information
ORCID Icon show all
Pages 24-33 | Received 10 Jan 2019, Accepted 14 Apr 2019, Published online: 29 May 2019

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial
Source: Bentham Science Publishers Ltd.
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Source: Massachusetts Medical Society
Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials
Source: Oxford University Press (OUP)
Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
Source: Ovid Technologies (Wolters Kluwer Health)
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy
Source: Ovid Technologies (Wolters Kluwer Health)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
Source: Taylor & Francis
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Source: Elsevier BV
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
Source: Taylor & Francis
RAPID antiretroviral therapy
Source: Ovid Technologies (Wolters Kluwer Health)
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Source: Ovid Technologies (Wolters Kluwer Health)
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial
Source: Public Library of Science (PLoS)
HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies
Source: Informa UK Limited
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Source: Elsevier BV
Clinical pharmacokinetics of antiretroviral drugs in older persons
Source: Informa Healthcare
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Source: American Medical Association (AMA)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Source: Elsevier BV
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Source: HAL CCSD
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
Source: Informa UK Limited
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Source: American Medical Association (AMA)
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Source: Ovid Technologies (Wolters Kluwer Health)
Sex-Based Outcomes of Darunavir–Ritonavir Therapy
Source: American College of Physicians
Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir
Source: Mary Ann Liebert Inc
A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV
Source: Springer Nature America, Inc

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.